Lee Edwards

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Novartis Ag. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lee Edwards. Retrieved from https://idiyas.com/inventor/lee-edwards

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 94.7

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 6.7

ph-index = 5

Forward Citations = 115(Granted Patents)

Location History:

Patridge Green, GB (2015)
Partridge Green, GB (2013 - 2018)
Horsham, GB (2010 - 2024)

Company Filing History:

19 out of 3,978

Novartis Ag

patents

Years Active: 2010-2024

Loading Chart...

Areas of Expertise:

Pyridine Derivatives

Pyrazine Compounds

Chronic Bronchitis

Cystic Fibrosis

Epithelial Sodium Channel

ENaC Blockers

Respiratory Disorders

PI3 Kinase Inhibitors

Heterocyclic Compounds

VR1 Receptors

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11911371 - Pyridine and pyrazine derivative for the treatment of chronic bronchitis (2024-02-27),

2. 10117858 - Pyridine and pyrazine derivative for the treatment of CF (2018-11-06),

3. RE46757 - Pyridine and pyrazine derivative for the treatment of CF (2018-03-19),

4. 9643983 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2017-05-09),

5. 9522149 - Pyrazine derivatives as ENaC blockers (2016-12-20),

6. 9365552 - Pyridine and pyrazine derivative for the treatment of CF (2016-06-14),

7. 9139586 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2015-09-22),

8. 9056867 - N-substituted heterocyclyl carboxamides (2015-06-16),

9. 9050339 - Pyrazine derivatives as ENaC blockers (2015-06-09),

10. 9034879 - Heterocyclic compounds for the treatment of CF (2015-05-19),

11. 8901134 - Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders (2014-12-02),

12. 8846687 - Pyrazine compounds as PI3 kinase inhibitors (2014-09-30),

13. 8697687 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2014-04-15),

14. 8476269 - Pyridine and pyrazine derivative for the treatment of CF (2013-07-02),

15. 8372845 - Pyrazine derivatives as enac blockers (2013-02-12),

Title: Innovations in Pharmaceutical Science: The Contributions of Lee Edwards

Introduction:

Lee Edwards, an accomplished inventor based in Horsham, GB, has made significant strides in the field of pharmaceutical sciences. With 19 patents to his name, Edwards specializes in developing innovative derivatives that address serious health conditions.

Latest Patents:

Among his latest inventions are two pivotal patents focused on pyridine and pyrazine derivatives aimed at the treatment of chronic bronchitis and cystic fibrosis. These innovative compounds work by restoring or enhancing the function of the cystic fibrosis transmembrane conductance regulator (CFTR). The scope of these inventions extends to treating various conditions such as chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia, and even constipation due to conditions like IBS, IBD, and opioid-induced complications. These pharmaceutical compositions reveal Edwards' commitment to advancing therapeutic options for patients facing these debilitating diseases.

Career Highlights:

Lee Edwards is currently affiliated with Novartis AG, a leading global healthcare company. His work demonstrates a robust understanding of medicinal chemistry and a dedication to patient care through innovative research and development. His extensive knowledge aids in pushing the boundaries of what is possible in pharmaceutical treatments.

Collaborations:

Throughout his career, Edwards has collaborated with talented professionals in the field, including Catherine Howsham and Emma Budd. These partnerships not only enhance the research and development process but also contribute to a collaborative environment that facilitates groundbreaking innovations in medicine.

Conclusion:

In summary, Lee Edwards' contributions to the pharmaceutical industry through his patents highlight the importance of innovation in treating complex medical conditions. His dedication to enhancing therapeutic functionality not only benefits his colleagues and company but also offers hope to patients worldwide. Through the continued support of collaborative efforts and inventive research, Edwards stands as a pivotal figure in transforming healthcare solutions.

Profile summary based on public USPTO records.